New York, NY, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Hereditary Cancer Testing Market by Diagnosis Type (Biopsy, Imaging and Others), By End-User (Hospitals, Clinics, and Diagnostic Centers), and by Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 - 2024”. According to the report, global hereditary cancer testing market was valued at approximately USD 98.06 billion in 2017 and is expected to generate revenue of around USD 147.62 billion by end of 2024, growing at a CAGR of around 6% between 2018 and 2024.
Hereditary cancer testing is a process that identifies an inherited gene mutation that increases the risk of cancer development. Hereditary cancer testing majorly covers predictive genetic testing and clinical DNA sequencing. In predictive genetic testing, the patient’s family history is analyzed for any inherited mutation from ancestry. This test is very useful for testing many genetic mutations at a time. It is similar to other cancer testing techniques and it includes lab tests, imaging procedures, and biopsy. This test does not diagnose whether a person is suffering from cancer it only recognizes if a person is bearing a change in genes which increases the risk of cancer.
Browse through 54 Tables & 12 Figures spread over 110 Pages and in-depth TOC on “Global Hereditary Cancer Testing Market: By Type, Size, Trends, Growth Analysis and Forecast, 2017 - 2024”.
Request Free Sample Report of Global Hereditary Cancer Testing Market Report @ https://www.zionmarketresearch.com/sample/hereditary-cancer-testing-market
The global hereditary cancer testing market is primarily driven by the worldwide demand for non-invasive techniques for detection of hereditary cancer. Other major factors include growing government funding for development of proper diagnostics and growing concerns for hereditary cancer propels the demand for the hereditary cancer testing market. The need for avoiding cancer in the future is likely to boost the demand for hereditary cancer testing market in the coming years. As the demand for non-invasive techniques is increasing histopathological detection still acts as a golden standard for identification of hereditary cancer.
The hereditary cancer testing market is segmented on the basis of diagnosis type which is further divided into biopsy, imaging, and others. Imaging segment is the leading division and is likely to maintain its position during the forecast period. Factors such as cost-effectiveness, performance ease, and accuracy anticipate for a valuable growth of this segment. On the basis of the end-user, the hereditary cancer testing market is segmented into hospitals, clinics, and diagnostic centers.
Download Free Report PDF Brochure: https://www.zionmarketresearch.com/requestbrochure/hereditary-cancer-testing-market
North America is the largest regional market and is expected to show significant growth rate over the forecasted period. Due to the high prevalence of cancer among the population coupled with the presence of many dominant players in the region the hereditary cancer testing market is witnessing significant growth.
Europe represents a developed regional market for hereditary cancer testing and is expected to witness a rapid growth in the years to come.
Browse the full "Hereditary Cancer Testing Market by Diagnosis Type (Biopsy, Imaging, and Others), By End-User (Hospitals, Clinics, and Diagnostic Centers), and by Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 - 2024" report at https://www.zionmarketresearch.com/report/hereditary-cancer-testing-market
Growth in the Asia Pacific region is expected due to increasing awareness about cancer. This region has been forecasted to witness scores of opportunities in the global hereditary cancer testing market. In the Middle East & Africa; African region is projected to register a moderate growth rate due to growing healthcare concerns and changing government policies. Latin America is expected to experience moderate growth over the forecast period.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/hereditary-cancer-testing-market
Some of the key players in the hereditary cancer testing market are Myriad Genetics, Myogenes, Laboratory Corporation of America, Biocartis NV, Quest Diagnostics, Pathway Genomics, Invitae Corporation, and Strand Life Sciences Pvt. Ltd., among others.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/3262
This report segments the global hereditary cancer testing market is as follows:
Global Hereditary Cancer Testing Market: by Diagnosis Type
Global Hereditary Cancer Testing Market: by End-User
Global Hereditary Cancer Testing Market: by Region
Browse More Related Reports:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Blog: http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651